Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Sutro Biopharma, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- −9 vs. Q4 2024
- Shares held
- 61.5M
- −1.11M (−1.8%) vs. Q4 2024
- Total value
- $40.0M
- −$75.1M (−65.3%) vs. Q4 2024
- New holders
- 18
- 39 more added
- Sold out
- 27
- 32 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting STRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 100 | $545.7M |
| Q1 2026 | 78 | $358.3M |
| Q4 2025 | 63 | $64.8M |
| Q3 2025 | 88 | $46.4M |
| Q2 2025 | 101 | $39.6M |
| Q1 2025 | 113 | $40.0M |
| Q4 2024 | 123 | $117.6M |
| Q3 2024 | 130 | $216.4M |
| Q2 2024 | 119 | $185.1M |
| Q1 2024 | 117 | $301.7M |
| Q4 2023 | 114 | $238.7M |
| Q3 2023 | 109 | $194.3M |
| Q2 2023 | 120 | $251.6M |
| Q1 2023 | 116 | $247.5M |
| Q4 2022 | 119 | $403.7M |
| Q3 2022 | 113 | $279.6M |
| Q2 2022 | 115 | $240.9M |
| Q1 2022 | 114 | $342.2M |
| Q4 2021 | 117 | $593.2M |
| Q3 2021 | 120 | $752.5M |
| Q2 2021 | 124 | $766.7M |
| Q1 2021 | 138 | $1.01B |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Sutro Biopharma, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Goldman Sachs Group Inc | 1,712,115 | $1.11M | 0.00% | −2,307−0.1% | Reduced |
| Geode Capital Management, LLC | 1,889,272 | $1.23M | 0.00% | +35,255+1.9% | Added |
| Adage Capital Partners GP, L.L.C. | 2,000,000 | $1.30M | 0.00% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 2,196,814 | $1.43M | 0.25% | 00.0% | Unchanged |
| Eversept Partners, LP | 2,292,261 | $1.49M | 0.17% | +1,597,853+230.1% | Added |
| Vestal Point Capital, LP | 2,600,000 | $1.69M | 0.12% | +30,000+1.2% | Added |
| Merck & Co., Inc. | 2,723,509 | $1.77M | 1.08% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 3,134,586 | $2.04M | 0.01% | +1,382,661+78.9% | Added |
| Vanguard Group Inc | 4,395,244 | $2.86M | 0.00% | +186,744+4.4% | Added |
| Ra Capital Management, L.P. | 4,434,637 | $2.89M | 0.05% | +4,434,637 | New |
| Kynam Capital Management, LP | 5,441,447 | $3.54M | 0.30% | +1,800,000+49.4% | Added |
| BlackRock, Inc. | 6,204,784 | $4.04M | 0.00% | −1,388,407−18.3% | Reduced |
| Suvretta Capital Management, LLC | 7,462,495 | $4.86M | 0.20% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −2,197,538−100.0% | Sold out |
| MPM Oncology Impact Management LP | 0 | $0 | 0.00% | −2,160,062−100.0% | Sold out |
| Parkman Healthcare Partners LLC | 0 | $0 | 0.00% | −1,727,925−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −859,373−100.0% | Sold out |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | $0 | 0.00% | −326,317−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −196,800−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −180,401−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | −132,406−100.0% | Sold out |
| Thrivent Financial for Lutherans | 0 | $0 | 0.00% | −97,096−100.0% | Sold out |
| Public Employees Retirement System of Ohio | 0 | $0 | 0.00% | −96,657−100.0% | Sold out |
| American Century Companies Inc | 0 | $0 | 0.00% | −93,033−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −91,797−100.0% | Sold out |
| Aristides Capital LLC | 0 | $0 | 0.00% | −79,400−100.0% | Sold out |
| Baillie Gifford & Co | 0 | $0 | 0.00% | −48,791−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −23,390−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −14,309−100.0% | Sold out |
| BKD Wealth Advisors, LLC | 0 | $0 | 0.00% | −12,840−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −1,190−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −1,137−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,350−100.0% | Sold out |
| Smartleaf Asset Management LLC | 0 | $0 | 0.00% | −511−100.0% | Sold out |
| Aquilo Capital Management, LLC | 0 | $0 | 0.00% | −498−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −350−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −58−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |